Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of REOLYSIN in Combination With Gemcitabine for Patients With Advanced Pancreatic Adenocarcinoma

NCT00998322 is registered in ClinicalTrials.gov with Oncolytics Biotech as lead sponsor.

NCT NCT00998322
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00998322 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of REOLYSIN in Combination With Gemcitabine for Patients With Advanced Pancreatic Adenocarcinoma
Lead sponsor
Oncolytics Biotech
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2009
Completion date
February 28, 2015
Enrollment
34 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic adenocarcinoma